Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-678-5 | CAS number: 68603-87-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.3 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Dose descriptor starting point:
- NOAEC
- Value:
- 87 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 107.4 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The NOAEL of 87 mg/kg bw/day that was considered relevant for human risk assessment purposes, obtained in an oral study with subchronic gavage exposure of rats on 7 days/week performed similar to OECD TG 408 (Monsanto, 1985) is taken forward for DNEL derivation. The corrected inhalatory NOAEC for workers as starting point is calculated with 107.4 mg/m³ according to the conditions given below.
For the inhalation route there is no animal study available. Therefore, oral rat data is used to calculate a corresponding air concentration for humans and a route-to-route extrapolation for systemic effects is necessary to derive the correct starting point. In the case of oral-to-inhalation the inclusion of a default factor of 2 is recommended according to chapter R.8.4.2 of the ECHA guidance on information requirements and chemical safety assessment, chapter R.8: Characterisation of dose [concentration]-response for human health (version 2.1, November 2012). According to Figure R. 8-3 in the ECHA guidance on information requirements and chemical safety assessment, chapter R.8: Characterisation of dose [concentration]-response for human health (version 2.1, November 2012) additional correction is needed for scaling issues: Corrected inhalatory NOAEC = oral NOAEL * 50%/100% * 1/0.38 m³ per kg and day * 6.7 m³/10 m³ * 1.4 (for differences in experimental/human exposure conditions, i.e. 7 days/week in animal study versus 5 days/week for workers, see Appendix R.8-6 of ECHA Guidance R8). Based on the oral NOAEL of 87 mg/kg bw/day for systemic toxicity obtained in a study on rats with subchronic treatment) the starting point is calculated with 107.4 mg/m³.
- AF for dose response relationship:
- 1
- Justification:
- Since the starting point for the DNEL calculation is a NOAEL according to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor for dose response relationship is 1.
- AF for differences in duration of exposure:
- 2
- Justification:
- For differences in the experimental exposure duration (= subchronic) and the duration of exposure for the population and scenario under consideration (= chronic) according to Table R.8-5 of ECHA guidance R.8 a factor of 2 is considered.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Allometric scaling is already included in the route-to-route extrapolation for dose descriptor calculation as described in ECHA Guidance R.8.
- AF for other interspecies differences:
- 2.5
- Justification:
- A factor of 2.5 for remaining interspecies differences is suggested in ECHA guidance R.8.
- AF for intraspecies differences:
- 5
- Justification:
- According to chapter R.8.4.3.1 of ECHA guidance R.8 the default assessment factor to be applied for intraspecies differences in workers is 5.
- AF for the quality of the whole database:
- 1
- Justification:
- Default assessment factor for good/standard quality of database as suggested by ECHA guidance R.8.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- irritation (respiratory tract)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- irritation (respiratory tract)
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.22 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Dose descriptor starting point:
- NOAEL
- Value:
- 87 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 121.8 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The NOAEL of 87 mg/kg bw/day that was considered relevant for human risk assessment purposes, obtained in an oral study with subchronic gavage exposure of rats on 7 days/week performed similar to OECD TG 408 (Monsanto, 1985) is taken forward for DNEL derivation.
For the dermal route there is no animal study available. Therefore, oral rat data are used to calculate a corresponding dermal exposure dose for humans. On the assumption that, in general, dermal absorption will not be higher than oral absorption, no default factor (i.e. factor 1) should be introduced when performing oral-to-dermal extrapolation (ECHA guidance R.8, chapter 8.4.2). Thus, no modification of the dose descriptor starting point is warranted. However, since there are differences in experimental/human exposure conditions (7 days/week in animal study versus 5 days/week for workers) adaption with a factor of 1.4 seems appropriate (Appendix R.8-6 of ECHA Guidance R8). Based on the oral NOAEL of 87 mg/kg bw/day for systemic toxicity obtained in a study on rats with subchronic treatment, the starting point is calculated with 121.8 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- Since the starting point for the DNEL calculation is a NOAEL according to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor for dose response relationship is 1.
- AF for differences in duration of exposure:
- 2
- Justification:
- For differences in experimental exposure duration (= subchronic) and the duration of exposure for the population and scenario under consideration (= chronic) according to Table R.8-5 of ECHA Guidance R.8 an assessment factor of 2 is considered.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- According to Table R.8-3 of ECHA Guidance R.8 the allometric scaling factor for the rat when compared with humans is 4.
- AF for other interspecies differences:
- 2.5
- Justification:
- A factor of 2.5 for remaining interspecies differences is suggested in ECHA Guidance R.8.
- AF for intraspecies differences:
- 5
- Justification:
- According to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor to be applied for intraspecies differences in workers is 5.
- AF for the quality of the whole database:
- 1
- Justification:
- Default assessment factor for good/standard quality of database as suggested by ECHA guidance R.8.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - workers
Overall, the systemic toxicity of adipic acid is low; it is not sensitizing, not mutagen, not toxic to reproductive organs, not a developmental toxicant and showed no carcinogenic activity in a limited 2-year feeding study.
In a two-year feeding study, groups of 20 male rats were given 0.1, 1, 3 and 5 % of adipic acid in the diet (equivalent to doses of approximately 75, 750, 2250 and 3750 mg/kg bw/day). Groups of 10 or 19 female rats received food containing 0 or 1 % adipic acid, respectively (approx. 750 mg/kg bw/day). Body weights, food consumption and general appearance were recorded weekly throughout the experimental period. After 2 years, surviving rats were weighed, killed, and examined grossly. The brain, thyroid, lung, heart, liver, spleen, kidneys, adrenals and stomach of the animals were weighed. Microscopic examination of thyroid, lung, heart, liver, spleen, kidneys, adrenals, stomach, pancreas, bone marrow, large and small intestine uterus, ovaries and testes on a representative number of animals (no further information) was performed. The percent survival for each test group was higher than for the control group. There were no body weight differences during the test period in female and male rats treated with 0, 0.1 and 1 % adipic acid. The weight gains of the male rats receiving 3 and 5 % adipic acid were significantly less than the control groups. At necropsy there was no treatment related effect observed. Results of microscopic examination of the organs revealed no compound related effect. The NOAEL was 1 % for male and female rats (approx. 750 mg/kg bw/day) (Horn et al. 1957).
The dose of 750 mg/kg bw/day is thus considered as basis for DNEL derivation.
No reliable repeated inhalation or dermal toxicity studies are available for adipic acid.
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) has evaluated adipic acid and derived a maximum concentration at the workplace (MAK value, 2016) of 2 mg/m³ (inhalable fraction). This value was established by analogy to phosphorus acid until suitable data become available. ‘Taking into account the lower acidity (of adipic acid), this value is to be considered as the ‘worst-case’ for adipic acid.’
With regard to peak limitation an excursion factor of 2 is applied by MAK, also in analogy to phosphoric acid.
(The MAK collection for Occupational Health and Safety 2018, Vol 3, No 3)
A Threshold Limit Value (TLV-TWA) of 5 mg/m3 was established by the American Conference of Governmental Industrial Hygienists (ACGIH) in 2001, based on the data reported by Krapotkina et al (1981) that the threshold for irritation of the human eye was 20 mg/m3. Clinical examinations of worker engaged in adipic acid manufacture found that inhaling adipic acid produced functional disorders of the autonomic nervous system and gastrointestinal tract and in the mucosa of the upper respiratory tracts.
Occupational medical examination of the staff at Lanxess (7 persons) was performed. Examinations included medical history, physical examination, lung function, ECG/Ergometry, vision-testing and audiometry. Occupational medical surveillance did not reveal any health effects like irritations of the eyes, skin, mucosa membranes or upper respiratory tract which could be derived to be from possible exposure at workplace.
Adipic acid is listed as a GRAS (Generally Recognized as Safe) food additive by the FDA (Code of Federal Registrations, Title 21 - Food and Drugs, Part 184, FDA 1982)
General use (1977): A Group ADI (Acceptable Daily Intake) of 0-5 mg/kg bw was established for adipic acid and its potassium, sodium and ammonium salts in 1977 by JECFA (Joint FAO/WHO Expert Committee on Food Additives).
No safety concern at current levels of intake were seen by JECFA when used as a flavouring agent (FLAVOUR USE, JECFA 1999).
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.76 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Dose descriptor starting point:
- NOAEL
- Value:
- 87 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 37.8 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The NOAEL of 87 mg/kg bw/day that was considered relevant for human risk assessment purposes, obtained in an oral study with subchronic gavage exposure of rats on 7 days/week performed similar to OECD TG 408 (Monsanto, 1985) is taken forward for DNEL derivation. The corrected inhalatory NOAEC for the General Population is calculated with 37.8 mg/m³ according to the conditions given below.
For the inhalation route there is no animal study available. Therefore, oral rat data is used to calculate a corresponding air concentration for humans and a route-to-route extrapolation for systemic effects is necessary to derive the correct starting point. In the case of oral-to-inhalation the inclusion of a ‘default factor of 2 is recommended according to chapter R.8.4.2 of ECHA guidance R.8. According to Figure R. 8-3 in ECHA guidance R.8 additional correction is needed for scaling issues: Corrected inhalatory NOAEC = oral NOAEL * 0.5 * 1/1.15 m³ per kg and day (based on the oral NOAEL of 87 mg/kg bw/day for systemic toxicity).
- AF for dose response relationship:
- 1
- Justification:
- As the starting point for the DNEL calculation is a NOAEL according to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor for dose response relationship is 1.
- AF for differences in duration of exposure:
- 2
- Justification:
- For differences in the experimental exposure duration (= subchronic) and the duration of exposure for the population and scenario under consideration (= chronic) according to Table R.8-5 of ECHA Guidance R.8 a factor of 2 is considered.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Allometric scaling is already included in the route-to-route extrapolation for dose descriptor calculation as described in ECHA Guidance R.8.
- AF for other interspecies differences:
- 2.5
- Justification:
- A factor of 2.5 for remaining interspecies differences is suggested in ECHA Guidance R.8.
- AF for intraspecies differences:
- 10
- Justification:
- According to chapter R.8.4.3.1 of ECHA guidance R.8 the default assessment factor to be applied for intraspecies differences in the general population is 10.
- AF for the quality of the whole database:
- 1
- Justification:
- Default assessment factor for good/standard quality of database as suggested by ECHA guidance R.8.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- irritation (respiratory tract)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- irritation (respiratory tract)
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.43 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 87 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The NOAEL of 87 mg/kg bw/day that was considered relevant for human risk assessment purposes, obtained in an oral study with subchronic gavage exposure of rats on 7 days/week performed similar to OECD TG 408 (Monsanto, 1985) is taken forward for DNEL derivation.
For the dermal route there is no animal study available. Therefore, oral rat data are used to calculate a corresponding dermal exposure dose for humans. On the assumption that, in general, dermal absorption will not be higher than oral absorption, no default factor (i.e. factor 1) should be introduced when performing oral-to-dermal extrapolation (ECHA Guidance R.8, chapter 8.4.2). Thus, no modification of the dose descriptor starting point is warranted.
- AF for dose response relationship:
- 1
- Justification:
- As the starting point for the DNEL calculation is a NOAEL according to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor for dose response relationship is 1.
- AF for differences in duration of exposure:
- 2
- Justification:
- For differences in experimental exposure duration (= subchronic) and the duration of exposure for the population and scenario under consideration (= chronic) according to Table R.8-5 of ECHA Guidance R.8 a factor of 2 is considered.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- According to Table R.8-3 of ECHA Guidance R.8 the allometric scaling factor for the rat when compared with humans is 4.
- AF for other interspecies differences:
- 2.5
- Justification:
- A factor of 2.5 for remaining interspecies differences is suggested in ECHA Guidance R.8.
- AF for intraspecies differences:
- 10
- Justification:
- According to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor to be applied for intraspecies differences in the general population is 10.
- AF for the quality of the whole database:
- 1
- Justification:
- Default assessment factor for good/standard quality of database as suggested by ECHA guidance R.8.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.43 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 87 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The NOAEL of 87 mg/kg bw/day that was considered relevant for human risk assessment purposes, obtained in an oral study with subchronic gavage exposure of rats on 7 days/week performed similar to OECD TG 408 (Monsanto, 1985) is taken forward for DNEL derivation.
Oral data from the rat are used to decide on a corresponding oral dose for humans. Therefore, a route-to-route extrapolation is not necessary and the NOAEL from the rat study is used as starting point.
- AF for dose response relationship:
- 1
- Justification:
- As the starting point for the DNEL calculation is a NOAEL according to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor for dose response relationship is 1.
- AF for differences in duration of exposure:
- 2
- Justification:
- For differences in the experimental exposure duration (= subchronic) and the duration of exposure for the population and scenario under consideration (= chronic) according to Table R.8-5 of ECHA guidance R.8 a factor of 2 is considered.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- According to Table R.8-3 of ECHA Guidance R.8 the allometric scaling factor for the rat when compared with humans is 4.
- AF for other interspecies differences:
- 2.5
- Justification:
- A factor of 2.5 for remaining interspecies differences is suggested in ECHA Guidance R.8.
- AF for intraspecies differences:
- 10
- Justification:
- According to chapter R.8.4.3.1 of ECHA Guidance R.8 the default assessment factor to be applied for intraspecies differences in the general population is 10.
- AF for the quality of the whole database:
- 1
- Justification:
- Default assessment factor for good/standard quality of database as suggested by ECHA guidance R.8.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - General Population
Carboxylic acids, di-, C4-6 is a multi-constituent substance composed of 3 main constituents, i.e. adipic acid, glutaric acid, and succinic acid. The three constituents have the same core structure, and same acid moieties, and differ solely in chain length (C6-, C5-, and C4-dicarboxylic acid). For read-across purposes the constituent adipic acid (C6-dicarboxylic acid) is used as source. Target and source as well as the two other constituents show a very similar toxicological profile (For detailed information see the RAAF document attached to the IUCLID: ‘Justification for a read-across approach from Adipic acid (CAS No. 124-04-9) [Source] to Carboxylic acids, di-, C4-6 (CAS No. 68603-87-2) [Target]).
Based on the acidic nature local toxicity is the critical effect in toxicological studies. Carboxylic acids, di-, C4-6 was shown to induce moderate to severe eye irritation in rabbits, leading to classification with Eye Damage 1. Regarding skin irritation only slight and reversible reddening to rabbit skin was induced, and no skin sensitizing effects were recorded.
After acute and repeated oral exposure to high doses general toxicity became obvious. No specific target organs could be identified. In a sub-chronic gavage study observed effects included weight reduction, reduced food consumption, clinical observation of labored breathing and/or rale, pointing to irritation in the gastrointestinal tract as driver of toxicity. Bolus administration of Carboxylic acids, di-, C4-6 is expected to be the reason for the NOEL of 87 mg/kg bw/day.
Carboxylic acids, di-, C4-6 did not exert gene mutations in vitro in bacteria and mammalian cells. A clastogenic effect seen at high and cytotoxic concentrations in vitro could not be reproduced in a mouse chromosomal aberration assay in vivo. Overall, no relevant mutagenic effects were recorded.
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) has evaluated the three constituents of Carboxylic acids, di-, C4-6, i.e. adipic acid, glutaric acid and succinic acid and derived a maximum concentration at the workplace for each of the constituents (MAK value, 2017a and b, 2019) of 2 mg/m³ (inhalable fraction). This value was established by analogy to phosphorus acid until suitable data become available and can be considered as worst-case.
(The MAK collection for Occupational Health and Safety, 2017, Vol 3, No 3; 2017, Vol 3, No. 2; 2019, Vol 4, No.2)
A Threshold Limit Value (TLV-TWA) of 5 mg/m3 was established for adipic acid by the American Conference of Governmental Industrial Hygienists (ACGIH) in 2001, based on the data reported by Krapotkina et al (1981) that the threshold for irritation of the human eye was 20 mg/m3. Clinical examinations of worker engaged in adipic acid manufacture found that inhaling adipic acid produced functional disorders of the autonomic nervous system and gastrointestinal tract and in the mucosa of the upper respiratory tracts.
Occupational medical examination of the staff at Lanxess (7 persons) was performed. Examinations included medical history, physical examination, lung function, ECG/Ergometry, vision-testing and audiometry. Occupational medical surveillance did not reveal any health effects like irritations of the eyes, skin, mucosa membranes or upper respiratory tract which could be derived to be from possible exposure at workplace. Parallel to the medical examination the concentration of those hazardous substances in the air at the workplace were determined. The maximum concentration of adipic acid and glutaric acid were 11.6 mg/m3 and 1.23 mg/m3, respectively, between 2006 and 2009 (Currenta 2010).
With the aim to evaluate whether it would be possible to define a DNEL for local respiratory irritation of substances with reliable data to evaluate systemic toxicity, but with a lack of inhalation toxicity information despite existing indication of a local irritation potential, the Working Group Toxicology of the German Chemical Industry Association (VCI) assessed the relationship between established occupational exposure limit values and classification for local irritation and corrosion (Messinger, Reg Toxicol Pharmacol 58, 2014, 317-324). The experts developed upper boundary values for irritating and/or corrosive compounds based on available data. In particular the expert TF evaluated the German MAK-values published in the TRGS900 in 2009. For irritating compounds labelled with R36 or R38 but without relevant inhalation toxicity data available the TF developed a generic upper boundary value of 10 mg/m3; for compounds with corrosive properties (R34 or R35) a respective value of 1 mg/m3 is developed. Carboxylic acids, di-, C4-6 induces only slight irritation to rabbit’s skin but severe damage to rabbit eyes and is thus labelled with R41 (Eye Damage 1). The expert TF did not indicate a threshold for compounds labelled solely with R41. This hazard is thus covered by allocation to the moderate hazard band.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.